POULTRY INDONESIA


Poultry TechniClass

Program Vaksinasi Tepat, Produktivitas Broiler Meningkat

Didukung oleh :

Boehringer Ingelheim

POKPHAND



Rabu
28
Sept 2022
09.30-13.00 WIB

Drh. Titis Wahyudianto
Poultry Technical Manager West



BDABLEN

3 GENERATION OF IBD VACCINES

FITUR

BDABLEN



Vaksin *live* IBD 'Antigen-antibody complex' (Icx)

THE ORIGINAL IBD ANTIGEN-ANTIBODY COMPLEX


Vaksin kering beku dalam sediaan botol vial
Penyimpanan : 2 to 7°C

A vaccine that contains a live intermediate plus IBD virus strain (Winterfield 2512), mixed with IBD antiserum.

Kesimbangan yang sempurna antara strain virus vaksin IBD *live* dan antibodi virus IBD poliklonal

FITUR

BDABLEN



- ***BDA Blen Antigen-Antibody complex*** **tidak dinetralkan oleh MAB IBD seperti layaknyan vaksin IBD tradisional.**
- **BDA Blen mulai bekerja saat MAB IBD melemah untuk selanjutnya menggertak kekebalan adaftif terhadap IBD.**
- **Terbukti aman dan efisien.**
- **Terbukti melindungi terhadap serangan virus lapang : IBD klasik, IBD virulen dan IBD sangat virulen (tidak untuk IBD variant)**

KARAKTERISTIK

BDABLEN

PRINSIP: formulasi yang **seimbang** campuran **vaksin live IBDV** Strain Winterfield 2512 & antibodi **poliklonal IBDV**

AVIAN DISEASES 39:687–699, 1995

Determination of Optimum Formulation of a Novel Infectious Bursal Disease Virus (IBDV) Vaccine Constructed by Mixing Bursal Disease Antibody with IBDV

C. E. Whitfill,[AE] E. E. Haddad,[A] C. A. Ricks,[A] J. K. Skeeles,[B]
L. A. Newberry,[B] J. N. Beasley,[B] P. D. Andrews,[B]
J. A. Thoma,[C] and P. S. Wakenell[D]

[A]EMBREX Inc., P.O. Box 13989, Research Triangle Park, North Carolina 27560
[B]Department of Poultry Science
[C]Department of Chemistry and Biochemistry,
University of Arkansas, Fayetteville, Arkansas 72701
[D]Department of Population Health and Reproduction,
University of California, Davis, California 95616

Received 22 December 1994

TARGET FORMULA CRITERIA:

- ❑ Keamanan
- ❑ Efikasi / Immunogenisitas

FAKTA

BDABLEN

In 1996, BDA BLEN™ was the first IBD antigen-antibody complex vaccine ever registered. Since 2001, BDA BLEN™ has been produced by Merial and distributed by another laboratory under a different trade name. To date, over 10 billion birds have received BDA BLEN™ worldwide.


BAGAIMANA BDA BLEN BEKERJA?

BDABLEN

- Setelah vaksinasi, vaksin ICx beredar didalam darah
- Vaksin menuju target organ baik di limpa atau di BF
- Di limpa, ICx ditangkap oleh *follicular dendritic cells (FDC)*, sedangkan di BF mereka ditangkap oleh folikel-folikel sel B melalui reseptor Fc dan C3. Vaksin kemudian diikat yang memungkinkan mereka untuk berdiam untuk waktu yang lama di bursa
- Setelah MDA cukup rendah untuk tidak menetralkan strain vaksin *intermediate plus*, virus akan mulai bereplikasi (kira-kira 10 hari pasca vaksinasi, Jeurissen, 1998)

→ virus vaksin mulai bereplikasi bergantung pada lemahnya MAB pada tiap-tiap individu anak ayam.

→ BDA Blen bekerja individual mesikipun dengan MAB yang berbeda-beda



- Masih ada *immunity gap*.

BROILER SHIELD HIGH PROTECTION PROGRAM

DATA LAPANG

BDABLEN

GROW BEYOND CHALLENGES

ASSESSMENT OF THE BENEFITS PROVIDED BY AN IBD IMMUNE COMPLEX VACCINE IN BROILERS IN FIELD CONDITIONS IN ECUADOR.

Orlando BOHORQUEZ [1], Juan Carlos GONZALEZ [1], Camilo MEDINA [2] Francisco PEROZO [3].

[1] Nutrientes Avicolas, Cali, Colombia. [2] Universidad Industrial Santander, Bucaramanga, Colombia. [3] Boehringer Ingelheim, Bogotá, Colombia.

A total of 1.511.000 birds were evaluated during three runs in multiple flocks (654.000 birds vaccinated with vaccine A and 858.000 with immune complex vaccine B). Serology (IDEXX ELISA), histopathology (21, 25 and 28 days) and productive parameters were used to compare the two vaccination programs. No statistical differences were observed in the serological response to IBD and no evidence of IBD induced immunosuppression (no main microscopic differences) within the two vaccination programs were reported. No statistical differences where observed in mortality among the groups.

RESULTS

The overall health status benefited from changing the vaccination program to include vaccine A (Boeheringer Ingelheim immune complex) for Gumboro disease control as demonstrated by an improvement in the productive parameters evaluated. In a large industrial trial with total of 1.511.000 birds and three continuous run over a 9 month period multiples variables come along. Depending on the flocks the slaughter age fluctuated between 35 and 49 days due to marketing restrains, the climate and feed ingredient quality variations will happen in industrial trial generating useful data for decision making process in real life. The continuous use of the vaccination program A allowed higher average body weights an improvement in other productivity indexes.

PARAMETER	VACCINE A	VACCINE B	DIFFERENCE
Daily weight gain (g)	56,38	52,46	+ 3,92g
Final weight (g)	2470	2423	+ 47g
FCR	1817	2011	- 0,194g
EEI	296	245	+ 51g
Productivity Index	75,10	60,38	+ 15,28g
Mortality %	4,62	6,14	- 1,52g

Boehringer Ingelheim

PREVENTION WORKS
Shaping the future of poultry health

BROILER SHIELD HIGH PROTECTION PROGRAM

DATA LAPANG

BDABLEN


GROW BEYOND CHALLENGES

ASSESSMENT OF THE BENEFITS PROVIDED BY AN IBD IMMUNE COMPLEX VACCINE IN BROILERS IN FIELD CONDITIONS IN ECUADOR.

Orlando BOHORQUEZ [1], Juan Carlos GONZALEZ [1], Camilo MEDINA [2] Francisco PEROZO [3].

[1] Nutrientes Avicolas, Cali, Colombia. [2] Universidad Industrial Santander, Bucaramanga, Colombia. [3] Boehringer Ingelheim, Bogotá, Colombia.

CONSOLIDATED DIFFERENCES



CONCLUSIONS


- ☑ This report demonstrates that the use of a single dose of the a immune complex vaccine A (Boeheringer Ingelheim) allowed IBDV control and provided with a better health status as demonstrated by the productive parameters when compared with vaccine B.
- ☑ After the statistical analysis Vaccine A vaccinates gained 128 grs more, showed a lower feed conversion rate (-0,095 points) and obtained better European productivity index (+25,95) when compared with B vaccinates suggesting the suitability of using Vaccine B for IBDV control under field conditions in Ecuador.
- ☑ No differences in serology, mortality or histopathology lesions were observed aming the groups.


Boehringer Ingelheim

PREVENTION WORKS
Shaping the future of poultry health

DATA TRIAL

- Periode Trial : 16 Augustus – 20 September 2022
- BDA Blen VS 4 produk Icx dan serupa di Indonesia
- Data mentah
- Sedang proses : Analisa Titer IBD dan ND
  Histopat BF
  PCR BF







Rataan	GROUP					
	G2	G3	G4	G5	G6	G7
BW (gram)	1743	1779	1672	1715	1705	1664
Feed (gram)	5.110	5.250	5.250	5.250	5.250	5.250
FCR	2,93	2,95	3,14	3,06	3,08	3,16

Boehringer Ingelheim


PREVENTION WORKS
Shaping the future of poultry health

DATA TRIAL


GRUP G3
19/1
13/2
15/3
18/4
12/5
Bursa
Limpa
Tymus
Boehringer Ingelheim
BDABLEN
VAXXITEK
BURSAMETER
G3
Boehringer Ingelheim


G3
1 2 3 4 5 6 7 8 9 10
11 16 23 29 25 21 10 17 20 3
BURSA
Limpa
Thymus
G3
BDABLEN
VAXXITEK
Boehringer Ingelheim
G3
Boehringer Ingelheim

Concern terhadap *Immunity Gap*?



- **Jika tidak ingin adanya *immunity gap*, Gunakanlah Vaxxitek HVT+IBD, karena vaksin ini tidak dipengaruhi oleh MAB dan segera bereplikasi.**


VAXXITEK®
HVT+IBD
GET THE FULL
POTENTIAL

VAXXITEK® HVT+IBD:

... One giant leap for vaccination



Proteksi : **dini**

- Kekebalan diinduksi oleh bagian protein VP2 (bukan virus utuh)
  → tidak ada interferensi MAB
  → vaksinasi di hatchery

Proteksi : **luas**

- HVT = **live vector** → memberikan proteksi sistemik yang bagus

Proteksi : **jangka panjang**

- Replikasi vektor HVT, menghasilkan stimulasi antigenik jangka panjang yang konsisten

VAXXITEK® HVT+IBD: KEUNTUNGAN

Performans broiler yang jauh lebih baik

RESULTS

Impact on performance

Mortality:
decreased from **6.76% to 6.23%**
Condemnation rate:
decreased from **0.58% to 0.39%**
EPI (European Performance Index):
increased from **268 to 287**

Medical costssaving

33% saving

Causes of condemnation (examples)





Broiler – **Amerika Selatan** (Kasus IBDV tinggi, > 35 juta broilers divaksin dengan vHVT-IBD

RESULTS

Impact on performance

Culled chickens:
decreased from **1.90% to 1.42%**

Average daily weight gain:
increased from **45.45 g to 46.58 g**
(**35 to 34 days** for slaughter)

EPI (European Performance Index):
increased from **231 to 241**

Medical costssaving


0.37 US cents per 1.6 kg of body weight

Live bird market



Ayam kampung – **Afrika** (Kasus vIBD tinggi + ND, IB, AI > 150.000 divaksin dengan vHVT-IBD

PROGRAM VAKSINASI BROILER & VTS SUPPORT



Boehringer Ingelheim

LAB SUPPORT

- Medika Satwa Lab – Bogor : dikoordinasi oleh TM's
- Romindo Primavetcom
- GD Deventer – Holland *
- Anicon – Germany *
- Abadiah Laboratori Sdn Bhd – Malaysia *

** Silahkan kirim FTA Card ke :*

Drh. Titis Wahyudianto

Jl. Tebet Timur Raya No.1 RT01/RW07

Tebet – Jakarta Selatan – 12820

HP. 08111039544

PREVENTION WORKS

Shaping the future of poultry health

Boehringer Ingelheim

IBDBLEN

Bur706

BDABLEN



BI BRINGS NEWS INTO IBD PREVENTION

Boehringer Ingelheim Vetmedica GmbH

Binger Straße 173
55216 Ingelheim am Rhein
Germany

Phone +49 (0) 6132 770
Fax +49 (0) 6132 720

info@boehringer-ingelheim.de
www.boehringer-ingelheim.com

TERIMAKASIH



Copyright:
The concepts, statements and data elaborated in this presentation are the intellectual property of Boehringer Ingelheim Vetmedica GmbH and are subject to current copyright law. Complete or partial reproduction and passing on to third parties is not permitted.

Boehringer Ingelheim